DRI Healthcare Trust DHT.U

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today commented on the U.S. Food and Drug Administration's ("FDA") recently announced approval of Juvmo (tavapadon) for the treatment of motor symptoms that occur in Parkinson's disease. Juvmo (tavapadon) is a novel selective dopamine D1/D5 receptor partial agonist developed as a once-daily oral treatment for Parkinson's disease, for use both with and without levodopa.

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced that it has entered into purchase agreements to acquire certain royalty participation rights in U.S. net sales of tavapadon from funds managed by Bain Capital ("Bain") and NovaQuest Capital Management ("NovaQuest"). The transaction is expected to close following approval of tavapadon by the U.S. Food and Drug Administration ("FDA") and the satisfaction of other customary closing conditions.

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced that it has received the Put Price of approximately US$178 million in connection with its previously announced exercise of the contractual put option with respect to its royalty participation right in EKTERLY (the "Put Option").

DRI Healthcare Trust (TSE:DHT.UN) reported record second-quarter financial results, with double-digit growth in total income, cash receipts and adjusted EBITDA, while also monetizing its Ekterly royalty investment and preparing to begin receiving royalties from newly approved thyroid eye disease tre

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, 2026. DRI Healthcare's second quarter 2026 financial statements and Management's Discussion & Analysis ("MD&A") have been filed on SEDAR+ (www.sedarplus.ca). All dollar amounts are expressed in U.S. dollars unless otherwise indicated.

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today noted the announcement by KalVista Therapeutics, Inc. ("KalVista"), that it has entered into a definitive agreement to be acquired by Chiesi Group, an international research-focused biopharmaceutical group (the "Transaction").

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare"), a global leader in providing financing to advance innovation in the life sciences industry, announces that it will hold a conference call to discuss its first quarter 2026 financial results on Friday, May 15, 2026, at 8:00 a.m. ET. DRI Healthcare will report its financial results on Thursday, May 14, 2026, after market close.